IQAI's Sponsored Phase I Clinical Trial is Open
IQ-AI Limited (OTCQB:IQAIF) has opened enrollment for its Phase I clinical trial of oral gallium maltolate (GaM), aimed at treating glioblastoma multiforme (GBM). Led by Dr. Jennifer Connelly and Dr. Christopher Chitambar at the Medical College of Wisconsin, the trial seeks to establish the optimal dose of GaM. Motivated by preclinical results showing tumor growth inhibition and increased survival rates, the project faced some delays due to the qualification of a new encapsulation supplier, now resolved. CEO Trevor Brown expressed enthusiasm about the trial's commencement.
- Enrollment for Phase I trial of oral gallium maltolate is now open.
- Trial aims to treat glioblastoma multiforme, a critical need in oncology.
- Encapsulation supply issues have been resolved, ensuring continuous supply of capsules.
- Preclinical studies indicated positive outcomes with GaM, such as tumor growth inhibition and increased survival.
- Delay in trial start due to the need for a new encapsulation supplier.
MILWAUKEE, WI / ACCESSWIRE / March 10, 2022 / IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is open for enrollment. The trial is being led by Dr. Jennifer Connelly, MD, Associate Professor of Neurology, and Dr. Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology, both at the Medical College of Wisconsin (MCW). Patient recruitment in the trial is underway and potential volunteers that meet the inclusion criteria have already been identified.
In April 2021, IQ-AI announced it would finance the Phase I study which is designed to determine the optimal dose of GaM that can be administered safely. It is the first-in-human clinical trial for an oral form of GaM to be used in patients to treat glioblastoma multiforme (GBM).
Motivation to fund this trial was provided in part by the results of a preclinical (animal) study led by Dr. Chitambar. In that study, treatment with oral GaM inhibited tumor growth and resulted in a significant increase in overall survival.
In September, the Company announced that a new encapsulation supplier was necessary to meet the demands of the trial and went through the efforts to secure and qualify a new supplier.
While the qualification of a new supplier imposed a delay to the start of the trial, a robust source of supply is now ready to provide an efficient and continuous distribution of capsules to enrolled patients for this Phase I as well as subsequent trials.
"I applaud the efforts of everyone involved in qualifying a new encapsulation supplier and preparing the necessary documentation to the FDA, and that the start of this much anticipated trial is now finally underway," said Trevor Brown, CEO of IQ-AI.
About IQ-AI Limited
IQ-AI Limited, (LON:IQAI) (OTCQB:IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.
Safe Harbor Statement
This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," or the negative of these words and/or similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. For example, statements about future revenues and the Company's ability to fund its operations and contractual obligations are forward looking and subject to risks. Several important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, the inability to raise capital to support the Company through its growth stage, the Company's inability to generate projected sales and trade relations between the United States and China. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations Contact:
Michael Porter, President
Porter, LeVay & Rose, Inc.
Tel: 212-564-4700
mike@plrinvest.com
SOURCE: IQ AI Ltd.
View source version on accesswire.com:
https://www.accesswire.com/692530/IQAIs-Sponsored-Phase-I-Clinical-Trial-is-Open
FAQ
What is the purpose of IQ-AI Limited's Phase I clinical trial?
When did IQ-AI Limited open enrollment for its clinical trial?
Who is leading the Phase I clinical trial for IQ-AI Limited?
What were the results of the preclinical study related to GaM?
How did supply chain issues impact the clinical trial of IQ-AI Limited?
